Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.

摘要: For risk-adaptive therapeutic approaches in multiple myeloma (MM) treatment, we analyzed treatment outcome according to situ hybridization (FISH) profiles investigate the prognostic and predictive values of structural variations a large series Asian population. A total 565 newly diagnosed patients with between January 2005 June 2015 were evaluated. FISH results showed del(17p13) 8.8% (29/331), del(13q14) 35.5% (184/519), t(14;16) 2.5% (8/326), t(4;14) 27.9% (109/390), IgH rearrangement 47.7% (248/520), +1q21 40.8% (211/517). The presence del(17p13), rearrangement, was associated worse overall survival. Interestingly, however, conferred little impact. Treatment-specific analysis revealed t(14;16), trisomy 1q21 unsatisfactory response bortezomib. On other hand, del(9p21) less likely benefit from lenalidomide. Autologous stem cell transplantation (autoSCT) effective 1q21. Predictive bortezomib autoSCT are seemingly universal, but marker for lenalidomide appears ethnicity-specific. Thus, MM should be interpreted regards patient's ethnicity.